What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To evaluate the therapeutic potential of CBX-663, a TCR-mimetic T-cell engager targeting TERT in AML.

December 8, 2025Blood

CBX–663, a novel TCR-mimetic T-cell engager targeting a telomerase reverse transcriptase (TERT) peptide-HLA complex, that exhibits potent efficacy against AML cells

View Full Paper

Ask AI

Bookmark

Authors

QYQunyan YuTufts University DODelainey O’ConnorFulcrum Therapeutics (United States)EMElizabeth M. McNallyHeart Failure & Transplant

Discussion

Member takes

Implication

Preclinical findings demonstrate CBX-663 targets TERT in acute myelogenous leukemia, suggesting improved cytotoxicity against leukemic stem cells with manageable safety profile.

Key Points

To evaluate the therapeutic potential of CBX-663, a TCR-mimetic T-cell engager targeting TERT in AML.
Developed CBX-663 using the T-Bolt® platform to engage TERT540/HLA-A*02:01 complexes on tumor cells.
Tested cytotoxicity in AML cell lines and primary AML blasts ex vivo.
Assessed safety through in vitro CFU assays and in vivo studies in humanized mice.
CBX-663 induced potent T-cell activation and cytotoxicity in AML cells with sub-nM affinity.
Targeted leukemic stem cells more effectively than AML lineages, showing promise against complex karyotypes.
Demonstrated an acceptable therapeutic index compared to standard CD123-targeting therapies.

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0e3 https://doi.org/10.1182/blood-2025-5047

View Full Paper

Ask AI

Bookmark

Implication

Preclinical findings demonstrate CBX-663 targets TERT in acute myelogenous leukemia, suggesting improved cytotoxicity against leukemic stem cells with manageable safety profile.

CBX–663, a novel TCR-mimetic T-cell engager targeting a telomerase reverse transcriptase (TERT) peptide-HLA complex, that exhibits potent efficacy against AML cells

Discussion

Member takes

Implication

Key Points

Cite This Study

CBX–663, a novel TCR-mimetic T-cell engager targeting a telomerase reverse transcriptase (TERT) peptide-HLA complex, that exhibits potent efficacy against AML cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider